Overview compounds Audited

Status of our innovative compounds (Status: December 31, 2008)

XLS

 

 

 

 

Therapeutic area

Compound

Indication

Status

1

Developed in cooperation with mit ImClone: Erbitux® is a trademark of ImClone Systems, a wholly owned subsidiary of Eli Lilly & Co.

2

Exclusive worldwide licensing rights acquired from Oncothyreon Inc.

3

Collaboration with Micromet AG

4

Collaboration with Rigel Pharmaceuticals Inc.

5

All rights acquired from Santhera Pharmaceuticals AG

6

Inlicensed from Idera Pharmaceuticals Inc.

7

Collaboration with LPath, Inc. ASONEP is a trademark of LPath, Inc.

8

Collaboration with Newron Pharmaceuticals S.p.A.

9

Collaboration with ZymoGenetics Inc.

10

Collaboration with Theratechnologies

11

Collaboration with Ambrx, Inc.

 

SCCHN: Squamous cell carcinoma of the head and neck

NSCLC: Non-small cell lung cancer

SCLC: Small cell lung cancer

OI/ART: Ovulation induction/Assisted reproductive technology

HARS: HIV-associated adipose redistribution syndrome

Oncology

Erbitux® (cetuximab)1

NSCLC

Filed

 

 

Adjuvant colorectal cancer

Phase III

 

 

Gastric cancer

Phase III

 

Stimuvax®2

NSCLC

Phase III

 

Cilengitide

Glioblastoma

Phase III

 

Erbitux® (cetuximab)1

Breast cancer

Phase II

 

Cilengitide

SCCHN

Phase II

 

Tucotuzumab celmoleukin (EMD 273066 / huKS-IL2)

SCLC

Phase II

 

EMD 273063 (hu14.18-IL2)

Pediatric neuroblastoma
and melanoma

Phase II

 

Adecatumumab (MT201)3

Solid tumors

Phase I

 

Aurorakinase inhibitor (AS703569)4

Solid tumors and hematological malignancies

Phase I

 

NHS-IL2-LT (EMD 521873)

Solid tumors

Phase I

 

DI17E6 (EMD 525797)

Solid tumors

Phase I

 

Eg 5 inhibitor (EMD 534085)

Solid tumors und hematological malignancies

Phase I

 

Survivac (cancer vaccine)

Solid tumors

Phase I

 

MEK inhibitor (AS703026)5

Solid tumors

Phase I

 

IMO-20556
(TLR9 immunomodulator)

Solid tumors

Phase I

 

Sonepcizumab (ASONEP™)7

Solid tumors

Phase I

Neuro-
degenerative Diseases

New formulation of Rebif®

Relapsing forms of multiple sclerosis (MS) EMEA: approved; FDA: filed

Approved/
filed

 

Clinically isolated syndrome

Phase III

Cladribine tablets

Relapsing forms of MS

Phase III

 

Clinically isolated syndrome

Phase III

Safinamide8

Early-stage Parkinson’s disease

Phase III

 

Mid- to late-stage Parkinson’s disease

Phase III

Atacicept9

Multiple sclerosis

Phase II

Autoimmune & Inflammatory Diseases

Atacicept9

Systemic lupus erythematosus

Phase III

 

Rheumatoid arthritis

Phase II

Fibroblast growth factor 189

Osteoarthritis

Phase I

Fertility

Hyperglycosylated FSH

Infertility (OI / ART)

Phase II

Endocrinology

Tesmarolin10

HIV patients with lipodystrophy (only U.S.)

Phase III

 

ARX 20111

Growth hormone deficiency

Phase I
previous page back   next next page

SERVICES

CHART GENERATOR

Important key figures

MORE ON OTHER WEBSITES

previous page back   next next page
top
Imprint, © Merck KGaA, Darmstadt, Germany, Last update 18.02.2009